Analyst Whit Mayo of Leerink Partners reiterated a Buy rating on BrightSpring Health Services, Inc. (BTSG – Research Report), with a price target of $26.50.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Whit Mayo has given his Buy rating due to a combination of factors including BrightSpring Health Services, Inc.’s strong financial performance and promising future outlook. The company reported impressive first-quarter results for 2025, with revenue and EBITDA surpassing expectations by 6.1% and 6.6% respectively, leading to an upward revision of their 2025 outlook. This performance was driven by both the Pharmacy and Provider segments, with the Pharmacy segment showing particularly strong growth.
Additionally, BrightSpring Health Services, Inc. raised its EBITDA guidance by $25 million, indicating anticipated growth of 24-27%, which reinforces confidence in the company’s organic growth potential. The acquisition of certain assets from AMED is also expected to contribute positively, although further details are awaited. These factors collectively support Whit Mayo’s decision to maintain a Buy rating for BrightSpring Health Services, Inc.
In another report released yesterday, BTIG also reiterated a Buy rating on the stock with a $25.00 price target.